Trial Profile
A Randomized, Phase 3 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment of Patients With Pancreatic Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs ERY-ASP (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Acronyms TRYbeCA-1
- Sponsors ERYtech Pharma
- 10 Mar 2022 This trial has been completed in Spain, according to European Clinical Trials Database record.
- 09 Feb 2022 Status changed from active, no longer recruiting to completed.
- 09 Feb 2022 This trial has been completed in Sweden (End Date: 18 Jan 2022), according to European Clinical Trials Database record.